Changes in Baseline PSA Levels in Japanese Men From 1988 to 2003

Ohi, Masaru; Ito, Kazuto; Yamamoto, Takumi; Miyakubo, Mai; Takechi, Hiroyuki; Kubota, Yutaka; Suzuki, Kazuhiro

doi:10.1016/j.urology.2008.03.014

Cited by 6 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ohi et al [11] suggested that investigating the changes in the detection rate of prostate cancer in the same region and comparing the detection rates among different regions might have several limitations such as: (a) differences in the screening modalities; (b) different cutoffs used for PSA tests for referral to biopsy; (c) discrepancies in the biopsy methods, and (d) differences in the biopsy compliance for men with abnormal PSA findings.…”

Section: Discussionmentioning

confidence: 99%

“…More recently, studies have shown that the baseline PSA level can predict the risk of developing prostate cancer, and one Japanese study showed that the baseline PSA levels in Japan from 1988 to 2003 remained stable over 16 years [8][9][10][11] . Therefore, we investigated the yearly changes in the baseline PSA levels in our hospital to determine the number of men with prostate cancer detected at periodic health exams at a health promotion center at our hospital from 1995 to 2008.…”

Section: Prostate Cancer In Koreamentioning

confidence: 99%

See 1 more Smart Citation

Prostate Cancer: Recent Trends in Korea

Hoon¹,

Chang²

2010

Urol Int

View full text Add to dashboard Cite

Introduction: We investigated the yearly changes in the baseline prostate-specific antigen (PSA) levels and the incidence of prostate cancer in men screened at our health promotion center from 1995 to 2008 to determine the trends in prostate cancer in Korea. Subjects and Methods: The participants were 6,007 men, who had PSA screening for the first time at the health promotion center. Changes in the baseline PSA levels, age, body mass index (BMI), and cholesterol levels were investigated. We evaluated the percentage of participants with a PSA level ≧2.0 and 4.0 ng/ml; the men were stratified by a 5-year age range, over two calendar years. In addition, we reviewed the results of their prostate biopsies. Results: The median baseline PSA level and the percentage of participants with a PSA level ≧2.0 and 4.0 ng/ml was not increased. The univariate and multivariate analyses, controlled for age and BMI, showed that two calendar years was not an independent predictive factor of the PSA level. The biopsy compliance rate increased from 36% during 1997–1998 to 70% during 2005–2006. Conclusions: The data from this study suggest that the increase in the incidence of prostate cancer might have been inaccurate in Korea.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Prostate Cancer In Koreamentioning

confidence: 99%

Prostate Cancer: Recent Trends in Korea

Hoon¹,

Chang²

2010

Urol Int

View full text Add to dashboard Cite

show abstract

“…These findings were similar to those in a previous Japanese study from 1988 to 2003. 7 These findings regarding serum PSA distribution suggest that there are no changes in the serum PSA levels in 54–69 years old men without prostate cancer in Japan, at least over the last two decades, and further longitudinal studies will solve the problem regarding the relationship between serum PSA level and environment factors in Asia.…”

Section: Discussionmentioning

confidence: 93%

“…On the other hand, changes in lifestyle may have affected the incidence of prostate cancer in recent decades in Japan. A previous study indicated that baseline PSA distribution of Japanese men did not change between 1988 and 2003; 7 however, there have been no reports regarding recent trends of PSA distribution. It is necessary to elucidate the trends in PSA distribution in middle-aged men to promote PSA-based population screening.…”

Section: Introductionmentioning

confidence: 91%

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan

et al. 2014

View full text Add to dashboard Cite

To clarify the recent trends in prostate-specific antigen (PSA) distribution in men in Japan, we analyzed the PSA distributions of men undergoing PSA-based population screening. We summarized the annual individual data of PSA-based population screening in Kanazawa, Japan, from 2000 to 2011, and analyzed baseline serum PSA values of the participants at the first population screening. Serum PSA distributions were estimated in all participants and those excluding prostate cancer patients according to age. From 2000 to 2011, 19 620 men participated aged 54–69 years old in this screening program. Mean baseline serum PSA level of all participants at the first screening was 2.64 ng ml−1 in 2000, and gradually decreased to approximately 1.30 ng ml−1 in 2006. That of participants excluding prostate cancer patients was 1.46 ng ml−1 in 2000, and there was no remarkable change during the study period. The 95th percentiles in the participants excluding prostate cancer patients detected at the first population screening of men aged 54–59, 60–64, and 65–69 years old were 2.90, 3.60, and 4.50 ng ml−1, respectively. After the commencement of population screening, the proportion of prostate cancer patients with high serum PSA levels decreased. However, there were no changes in serum PSA levels in men without prostate cancer. Age-specific PSA reference level of men without prostate cancer in Japan was similar to that in China and Korea.

show abstract

“…An advantage of the current study was that all of the participants were undergoing screening for the first time, and had their PSA measured in a standardized fashion using the Tosoh PSA II. Ohi, et al 18 investigated PSA distribution using a database. Their study included 32,274 men, aged 50-79 years old, who underwent first-time screening in Gunma Prefecture from 1988 to 2003.…”

Section: Discussionmentioning

confidence: 99%

Long‐term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population‐based PSA screening

Oki

Ito

Suzuki

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Japan has experienced a drastic increase in the incidence of prostate cancer (PC). To assess changes in the risk for PC, we investigated baseline prostate specific antigen (PSA) levels in first-time screened men, across a 25-year period. In total, 72,654 men, aged 50-79, underwent first-time PSA screening in Gunma prefecture between 1992 and 2016. Changes in the distribution of PSA levels were investigated, including the percentage of men with a PSA above cut-off values and linear regression analyses comparing log PSA with age. The 'ultimate incidence' of PC and clinically significant PC (CSPC) were estimated using the PC risk calculator. Changes in the age-standardized incidence rate (AIR) during this period were analyzed. The calculated coefficients of linear regression for age versus log PSA fluctuated during the 25-year period, but no trend was observed. In addition, the percentage of men with a PSA above cut-off values varied in each 5-year period, with no specific trend. The 'risk calculator (RC)-based AIR' of PC and CSPC were stable between 1992 and 2016. Therefore, the baseline risk for developing PC has remained unchanged in the past 25 years, in Japan. The drastic increase in the incidence of PC, beginning around 2000, may be primarily due to increased PSA screening in the country.

show abstract

Changes in Baseline PSA Levels in Japanese Men From 1988 to 2003

Cited by 6 publications

References 8 publications

Prostate Cancer: Recent Trends in Korea

Prostate Cancer: Recent Trends in Korea

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan

Long‐term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population‐based PSA screening

Contact Info

Product

Resources

About